$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx

$aldx Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000119312515376648 Filed on November 13, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.230M	$1.260M	$770.0K
YoY Change	21.78%	63.64%	54.0%
% of Gross Profit
Research & Development	$3.110M	$2.076M	$1.196M
YoY Change	122.14%	73.66%	79.52%
% of Gross Profit
Depreciation & Amortization	$10.00K	$10.00K	$0.00
YoY Change
% of Gross Profit
Operating Expenses	$4.340M	$2.076M	$1.196M
YoY Change	80.08%	73.66%	79.52%
Operating Profit		-$3.338M	-$1.968M
YoY Change		69.58%	68.73%
Interest Expense	-$20.00K	$28.08K	$41.07K
YoY Change	-33.33%	-31.63%	183.89%
% of Operating Profit
Other Income/Expense, Net		-$28.08K	-$41.07K
YoY Change		-31.63%	-100.39%
Pretax Income	-$4.360M	-$3.370M	-$2.010M
YoY Change	78.69%	67.66%	-121.59%
Income Tax
% Of Pretax Income
Net Earnings	-$4.360M	-$3.366M	-$2.009M
YoY Change	78.69%	67.51%	-121.58%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.35	-$0.36
Diluted Earnings Per Share	-$448.6K	-$0.35	-$0.36
COMMON SHARES
Basic Shares Outstanding	9.713M shares	9.713M shares	5.565M shares
Diluted Shares Outstanding		9.713M shares	5.565M shares

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.60M	$30.60M	$10.10M
YoY Change	224.71%	202.97%	260.71%
Cash & Equivalents	$14.65M	$30.62M	$10.14M
Short-Term Investments	$12.90M
Other Short-Term Assets	$500.0K	$600.0K	$200.0K
YoY Change	150.0%	200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$28.09M	$31.23M	$10.34M
YoY Change	220.65%	201.85%	269.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$80.33K	$88.46K	$5.768K
YoY Change	518.29%	1433.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00
YoY Change
Total Long-Term Assets	$116.6K	$124.7K	$5.768K
YoY Change	328.08%	2061.91%
TOTAL ASSETS
Total Short-Term Assets	$28.09M	$31.23M	$10.34M
Total Long-Term Assets	$116.6K	$124.7K	$5.768K
Total Assets	$28.20M	$31.35M	$10.35M
YoY Change	220.98%	202.89%	269.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$851.2K	$743.6K	$482.5K
YoY Change	149.39%	54.13%	382.47%
Accrued Expenses	$1.186M	$630.3K	$363.7K
YoY Change	30.56%	73.33%	263.66%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$77.55K	$0.00
YoY Change	0.0%
Total Short-Term Liabilities	$2.115M	$1.374M	$846.1K
YoY Change	59.32%	62.38%	323.07%
LONG-TERM LIABILITIES
Long-Term Debt	$1.211M	$1.281M	$1.241M
YoY Change	3.05%	3.24%	-91.32%
Other Long-Term Liabilities			$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$1.211M	$1.281M	$1.241M
YoY Change	3.05%	3.24%	-91.38%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.115M	$1.374M	$846.1K
Total Long-Term Liabilities	$1.211M	$1.281M	$1.241M
Total Liabilities	$3.326M	$2.655M	$2.087M
YoY Change	32.9%	27.22%	-85.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$58.60M	-$54.25M	-$44.07M
YoY Change	25.99%	23.1%
Common Stock	$83.49M	$82.94M	$5.565K
YoY Change	58.14%	1490311.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$24.88M	$28.70M	$8.264M
YoY Change
Total Liabilities & Shareholders Equity	$28.20M	$31.35M	$10.35M
YoY Change	220.98%	202.89%	269.66%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$4.360M	-$3.366M	-$2.009M
YoY Change	78.69%	67.51%	-121.58%
Depreciation, Depletion And Amortization	$10.00K	$10.00K	$0.00
YoY Change
Cash From Operating Activities	-$2.980M	-$2.880M	-$1.210M
YoY Change	85.09%	138.02%	132.69%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$60.00K	-$10.00K
YoY Change		500.0%
Acquisitions
YoY Change
Other Investing Activities	-$12.95M
YoY Change
Cash From Investing Activities	-$12.95M	-$60.00K	-$10.00K
YoY Change		500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-40.00K	-10.00K	-170.0K
YoY Change		-94.12%	-108.76%
NET CHANGE
Cash From Operating Activities	-2.980M	-2.880M	-1.210M
Cash From Investing Activities	-12.95M	-60.00K	-10.00K
Cash From Financing Activities	-40.00K	-10.00K	-170.0K
Net Change In Cash	-15.97M	-2.950M	-1.390M
YoY Change	891.93%	112.23%	-197.89%
FREE CASH FLOW
Cash From Operating Activities	-$2.980M	-$2.880M	-$1.210M
Capital Expenditures	$0.00	-$60.00K	-$10.00K
Free Cash Flow	-$2.980M	-$2.820M	-$1.200M
YoY Change	85.09%	135.0%	130.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9712521	shares
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10142137
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9712521	shares
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	425911	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9712521	shares
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	82931679
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	122664
CY2015Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	201604
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	28695363
CY2015Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1281088
CY2015Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	743623
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	630325
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-54246028
CY2015Q3	us-gaap	Liabilities Liabilities	2655036
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31350399
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	9712
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1373948
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4028645
CY2015Q3	us-gaap	Assets Assets	31350399
CY2015Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88463
CY2015Q3	us-gaap	Assets Current AssetsCurrent	31225700
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	607335
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30618365
CY2015Q3	aldx	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	36236
CY2015Q3	aldx	Accrued General And Administrative Expense Current AccruedGeneralAndAdministrativeExpenseCurrent	119663
CY2015Q3	aldx	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	186394
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3262354
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5565415	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5565415	shares
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	52790090
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	48839
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	444786
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	6284058
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1175481
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	77546
CY2014Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	341294
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	908724
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-46511597
CY2014Q4	us-gaap	Liabilities Liabilities	2503045
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8787103
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	5565
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1327564
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2014Q4	us-gaap	Assets Assets	8787103
CY2014Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12993
CY2014Q4	us-gaap	Assets Current AssetsCurrent	8759872
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	232568
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8527304
CY2014Q4	aldx	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	14238
CY2014Q4	aldx	Accrued General And Administrative Expense Current AccruedGeneralAndAdministrativeExpenseCurrent	101457
CY2014Q4	aldx	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	313642
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.50
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1100000	shares
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.00
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.50
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	211528	shares
CY2015Q1	us-gaap	Share Price SharePrice	20.00
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.33
CY2015Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2822500	shares
CY2015Q2	us-gaap	Proceeds From Repurchase Of Equity ProceedsFromRepurchaseOfEquity	19600000
CY2015Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1100000	shares
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7100000
CY2015Q1	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	0.125
CY2015Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	211528	shares
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1900000
CY2015Q1	aldx	Expiration Of Warrant ExpirationOfWarrant	P3Y
CY2015Q1	aldx	Average Trading Volume Of Common Stock AverageTradingVolumeOfCommonStock	50000	shares
CY2015Q1	aldx	Redemption Price Of Warrants RedemptionPriceOfWarrants	0.001
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.89
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3169115
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	43392	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	934032	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3272730	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3229338	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.21
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6107
	us-gaap	Net Income Loss NetIncomeLoss	-2742580
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7129232
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-2327502
	us-gaap	Interest Paid InterestPaid	77606
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	194200
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4859546
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2116966
	us-gaap	Investment Income Interest InvestmentIncomeInterest	3
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-9456734
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	170000
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	4053570
	us-gaap	Share Based Compensation ShareBasedCompensation	1571895
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	333082
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2327502
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6879783
	us-gaap	Interest Expense InterestExpense	210539
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6107
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	10055005
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2303854
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10055005
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	245788
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1571895
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2555692
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	138653
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-2125
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	140617
	us-gaap	Depreciation Depreciation	339
	aldx	Warrants Issued To Underwriter In Initial Public Offering WarrantsIssuedToUnderwriterInInitialPublicOffering	315388
	aldx	Issuance Of Common Stock Upon Cashless Net Exercise Of Warrant IssuanceOfCommonStockUponCashlessNetExerciseOfWarrant	1191365
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.94
	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>NATURE OF BUSINESS</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> Aldeyra Therapeutics, Inc. (the Company or Aldeyra) was incorporated in the state of Delaware. The Company is developing a treatment for diseases thought to be related to high levels of aldehydes, naturally occurring pro-inflammatory toxins.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company’s principal activities to date include raising capital and research and development activities.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6328628
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>2.</b></td> <td valign="top" align="left"><b>BASIS OF PRESENTATION</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The accompanying interim unaudited condensed financial statements and related disclosures are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s financial statements and related footnotes for the year ended December 31, 2014 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, which was filed with the Securities and Exchange Commission on March 23, 2015. The financial information as of September 30, 2015, the three and nine months ended September 30, 2015 and 2014 is unaudited, but in the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation of the financial position, results of operations and cash flows at the dates and for the periods presented of the results of these interim periods have been included. The balance sheet data as of December 31, 2014 was derived from audited financial statements. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> On January 14, 2015, the Company sold, in a private placement, an aggregate of approximately 1.1 million shares of common stock at a price of $7.00 per share. Investors received warrants to purchase up to approximately 1.1 million shares of common stock at an exercise price of $9.50. The Company raised approximately $7.1 million in net proceeds in the private placement of common stock and warrants. Additionally, on January 21, 2015, in a subsequent private placement, the Company sold an aggregate of 211,528 shares of common stock at a price of $9.33 per share and a warrant to purchase up to 211,528 shares of common stock at a price of $0.125 per share subject to the warrant. The Company raised approximately $1.9 million in net proceeds in the private placement of common stock and a warrant to purchase common stock. In both transactions, the exercise price of the warrants is $9.50 per share. The warrants will expire 3 years from their respective date of issuance. The warrants do not include a net-exercise feature. The warrants may be redeemed by the Company at a price of $0.001 per share upon notice to the holders thereof in the event that the closing bid for Aldeyra’s common stock for each of the fifteen consecutive trading days prior to such redemption is at least $20.00 per share and the average trading volume of Aldeyra’s common stock during such period is at least 50,000 shares per day. Following Aldeyra’s notification to the warrant holders of its exercise of the redemption right under the warrants, the warrant holders will have the option to exercise the warrants prior to the redemption date rather than having them redeemed. In addition, the Company raised approximately $19.6 million, after deducting underwriting discounts and commissions and other offering expenses, which closed on May 22, 2015, through the issuance and sale of 2,822,500 shares of common stock in a follow-on public offering, including shares sold pursuant to the underwriters exercise of their option to purchase additional shares of common stock.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company’s management believes that its currently available resources, including amounts potentially available under its credit facility (Note 5), will provide sufficient funds to enable the Company to meet its expected obligations into approximately 2017 based on the Company’s current business plan. However, these amounts will not be sufficient for the Company to commercialize its product candidates or conduct any substantial, additional development requirements requested by the U.S. Food and Drug Administration (FDA). Additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to secure additional capital, or meet financial covenants that could be implemented under the Company’s term loans in certain circumstances, it will be required to significantly decrease the amount of planned expenditures, and may be required to cease operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> Curtailment of operations would cause significant delays in the Company’s efforts to introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 18px">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <b><i>Recently issued accounting standards</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> In April 2015, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). The amendments in ASU 2015-03 require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for the Company in the first quarter of fiscal year 2017, with early adoption permitted. ASU 2015-03 should be applied on a retrospective basis to each individual period presented. Upon implementation, the change in reporting debt issuance costs will require the Company to reclassify any deferred financing costs from an asset to a reduction of the reported debt balance. The application of ASU 2015-03 is expected to reduce the Company’s total assets and liabilities but is not expected to have an impact on stockholders’ equity, results of operations or cash flows.</p> </div>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2461908	shares
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001341235
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M22D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y7M21D
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.00	pure
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Registrant Name EntityRegistrantName	ALDEYRA THERAPEUTICS, INC.
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8270405	shares
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	28061
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Share Based Compensation ShareBasedCompensation	1639930
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	22091061
	us-gaap	Interest Expense InterestExpense	84314
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8270405	shares
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
	dei	Trading Symbol TradingSymbol	ALDX
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y8M27D
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	86119
	us-gaap	Net Income Loss NetIncomeLoss	-7734431
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7734431
	us-gaap	Interest Paid InterestPaid	55775
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	21998
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	374767
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7650117
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-84314
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-7734431
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1639930
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3188176
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-86119
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	28505808
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4461941
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28505808
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-278401
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	402329
	us-gaap	Depreciation Depreciation	10649
	aldx	Number Of Incentive Plans NumberOfIncentivePlans	3	Incentive_Plan
	aldx	Deferred Offering Costs Not Yet Paid DeferredOfferingCostsNotYetPaid	36236
	aldx	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1.00	pure
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	934032	shares
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5565415	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5565415	shares
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-2009206
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2009206
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1968135
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-41071
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2009206
CY2014Q3	us-gaap	Interest Expense InterestExpense	41071
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1195668
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	457789
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	772467
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2461938	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9712521	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9712521	shares
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-3365687
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3365687
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3337606
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-28081
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3365687
CY2015Q3	us-gaap	Interest Expense InterestExpense	28081
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2076410
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	536269
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1261196

Files In Submission

Name	View Source	Status
0001193125-15-376648-index-headers.html	Edgar Link	pending
0001193125-15-376648-index.html	Edgar Link	pending
0001193125-15-376648.txt	Edgar Link	pending
0001193125-15-376648-xbrl.zip	Edgar Link	pending
aldx-20150930.xml	Edgar Link	completed
aldx-20150930.xsd	Edgar Link	pending
aldx-20150930_cal.xml	Edgar Link	unprocessable
aldx-20150930_def.xml	Edgar Link	unprocessable
aldx-20150930_lab.xml	Edgar Link	unprocessable
aldx-20150930_pre.xml	Edgar Link	unprocessable
d21464d10q.htm	Edgar Link	pending
d21464dex1021.htm	Edgar Link	pending
d21464dex311.htm	Edgar Link	pending
d21464dex312.htm	Edgar Link	pending
d21464dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx

2015 Q4 Form 10-Q Financial Statement

#000119312515376648 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALDX Aldeyra Therapeutics, Inc. Stock $aldx

2015 Q4 Form 10-Q Financial Statement

#000119312515376648 Filed on November 13, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx